ESTRO 2022 - Abstract Book

6-10 May 2022 ONSITE IN COPENHAGEN & ONLINE

Table of contents

SATURDAY 7 MAY 2022

Teaching lecture Developing a national infrastructure for proton beam therapy trials...................................................................... (abs. 1) The radiobiological clock in 2022............................................................................................................................. (abs. 2 - 3) Stereotactic radiotherapy in lung: Recent advances................................................................................................... (abs. 4) Palliative radiotherapy: Established standards and emerging concepts.................................................................. (abs. 5) Improving radiotherapy outcomes for vaginal tumours using a joint target concept............................................ (abs. 6) Commissioning and quality assurance of commercial in vivo dosimetry systems.................................................. (abs. 7) Monte Carlo dose calculation in modern day radiotherapy. ..................................................................................... (abs. 8) Patient education in 2022: Does the patient know better?........................................................................................ (abs. 9) Symposium Education in radiation oncology: Advances and opportunities........................................................................ (abs. 10 - 15) Debate This house believes that FLASH radiotherapy is a more promising avenue for the future of radiation oncology than particle radiotherapy...................................................................... (abs. 16 - 21) Symposium New developments in the treatment of oesophageal cancer........................................................................... (abs. 22 - 24) All the hassle with haematopoietic systems....................................................................................................... (abs. 25 - 28) Debate Soft tissue sarcoma: Brachytherapy and/or EBRT or IORT - Current evidence............................................... (abs. 29 - 33) Joint Symposium ESTRO-EFOMP: CT innovations: DECT and beyond............................................................................................ (abs. 34 - 37) Proffered Papers Intra-fraction and real-time motion management............................................................................................. (abs. 38 - 44) Symposium Learning about the patients we do not see: A focus on inequities in radiotherapy access and provision.. (abs. 45 - 47) Mini-Oral 01: Dosimetry......................................................................................................................................................... (abs. 48 - 55) 02: Health economics & healthcare systems...................................................................................................... (abs. 56 - 63) Poster Discussion 01: Image processing & analysis.......................................................................................................................... (abs. 64 - 75) 02: Palliation, mixed sites..................................................................................................................................... (abs. 76 - 87) Proffered Papers Proton beam therapy............................................................................................................................................ (abs. 88 - 93) Normal tissue radiobiology.................................................................................................................................. (abs. 94 - 99) Late-breaking.....................................................................................................................................................(abs. 100 - 106) Upper GI.............................................................................................................................................................(abs. 107 - 112) Physics................................................................................................................................................................(abs. 113 - 118)